The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

UK biotech firm Genus seeks approval to sell virus-resistant CRISPR pigs in China, world’s biggest pork market

| | May 17, 2019

British livestock genetics firm Genus agreed on [May 16] to license its know-how on virus-resistant pigs to Beijing Capital Agribusiness Co Ltd, which will seek regulatory approval for the pigs in the world’s biggest pork market.

Genus has a global patent for commercialization of pigs genetically edited to resist Porcine Reproductive and Respiratory Syndrome (PRRS), also known as blue-ear disease, which causes billion-dollar losses for the global pig industry each year.

Under the deal, BCA will set up Beijing Shou Nong Future Bio-Tech Co. Ltd that will fund the development of the market and seek approval for commercial production of pigs resistant to the virus. This is expected to take several years and cost tens of millions of dollars, said Genus in a statement.

Related article:  FDA rejects call for USDA takeover of CRISPR gene-edited animal regulation

Read full, original article: Genus shares surge on deal to market gene-edited pigs in China

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend